© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Brivaracetam traces its roots back to the early efforts in rational antiepileptic drug design during the late twentieth century. Scientists spent years exploring the structure-activity relationships of known anticonvulsants, seeking to boost potency and reduce unwanted effects. The effort to develop brivaracetam built on lessons learned from its chemical cousin, levetiracetam, a widely used antiepileptic agent introduced in the nineties. Researchers focused on enhancing the affinity for synaptic vesicle protein 2A, a key target involved in modulating neural excitability. Once the unique n-propyl side chain of brivaracetam surfaced during the screening, the compound advanced quickly through preclinical stages on the strength of robust anticonvulsant activity and a reassuring safety profile. Within a decade, research shifted it from laboratory curiosity to an actively marketed therapy, and chemical suppliers sought to meet growing demand for this key research reagent.
Brivaracetam reagent comes as a high-purity substance, preferred in anhydrous crystalline powder or granular forms for use in laboratories. This compound stands out for its precise targeting in neuroscience assays, its role in pharmaceutical synthesis, and its utility in chemical analysis protocols. Both academic investigators and developers in the pharma industry request it for mechanistic research, metabolite tracing, and for creating reference materials in stringent quality control environments. Its commercial labeling highlights rigorous identity testing, purity data, and batch traceability, catering to researchers who require dependable performance in sensitive applications.
Brivaracetam’s structure places it in the class of racetam compounds, with a 4-propylpyrollidin-2-one ring system. Its molecular formula, C11H20N2O2, weighs in at around 212.29 g/mol. In its pure state, brivaracetam shows up as a white to off-white crystalline solid. It dissolves freely in polar organic solvents such as DMSO and methanol but resists dissolution in water at room temperature. A melting point range of roughly 68°C to 72°C points to moderate thermal stability. Brivaracetam breaks down cleanly under routine mass spectrometry or NMR assays, making it a reliable candidate for analytical method development.
Reagent-grade brivaracetam boasts stringent purity standards, often reaching or exceeding 98%. Certificates of analysis accompany every batch, detailing identity confirmation methods, IR spectra, and residual solvent content. Labels typically display lot number, production date, recommended storage temperatures—often 2-8°C—and hazard codes as guided by international chemical safety norms. Packaging includes tamper-evidence features and moisture barriers. Suppliers also furnish Material Safety Data Sheets outlining the steps to handle, store, and dispose of this material.
Production of brivaracetam in the lab or industry involves a convergent synthesis, starting with amino acid-derived building blocks. Key steps include alpha-amino acid alkylation, followed by cyclization to assemble the pyrrolidone core. Chemists frequently use brominated intermediates and alkyl halides to introduce the n-propyl side chain. The process usually wraps up with careful purification through crystallization or preparative HPLC to yield a product fit for high-precision research. Every synthetic route carefully manages water content and pH, as these can trigger unwanted side reactions or reduce yield.
Brivaracetam’s reactive groups open pathways for further chemical modification. The pyrrolidone ring and terminal amide attract the attention of medicinal chemists interested in analog synthesis. Researchers look for ways to tweak these moieties—replacing the propyl group or introducing fluorine atoms—to screen for new therapeutic activities or probe receptor binding. Its robust core structure resists quick degradation, making it valuable in stability-indicating studies. Reductive and oxidative reactions involving brivaracetam fill out chemical libraries and support metabolism research.
Laboratories and inventory systems track brivaracetam under numerous synonyms and identifiers: UCB 34714, BRV, and its chemical name (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide. Custom reagents, salt forms, and isotopically labeled compounds appear under related catalog designations as researchers widen its use beyond primary drug formulation.
Handling brivaracetam as a reagent means working under established chemical safety practices. It ranks as a low-to-moderate hazard material, but demands care to prevent inhalation, skin, or eye exposure. Bench chemists must use gloves, lab coats, and fume hoods if powder handling or weighing is frequent. Spills call for gentle sweeping and cleanup with minimal dust generation. Good record-keeping in line with institutional chemical hygiene policies supports both individual safety and broader environmental stewardship.
Brivaracetam serves as a signature tool in neuropharmacology research, especially for studies focused on epilepsy and synaptic transmission. Its role extends into broader chemical biology, helping biochemists map protein-ligand interactions and identify off-target effects in central nervous system assays. In pharmaceutical development, brivaracetam becomes a spike-in reference standard, supporting quality control and batch release testing for finished products. Custom derivatization lets bioanalytical chemists develop sensitive liquid chromatography or mass spectrometric methods, critical for therapeutic drug monitoring and forensics.
Publications keep highlighting brivaracetam’s binding properties, rapid onset, and improved side effect profile over older anti-seizure compounds. Preclinical teams test analogues across a spectrum of animal models, hoping to untangle the complex actions on SV2A and related neural targets. Formulation scientists experiment with ways to boost solubility or extend duration of action, while regulatory groups keep a close eye on impurity profiling and method validation using standardized brivaracetam reagents. Academic-industrial partnerships keep the pipeline of discovery strong, with pre-competitive consortia sharing libraries for high-throughput screens.
Toxicology studies aim to flag off-target effects and unwanted pharmacological liabilities. Brivaracetam shows a clean record across acute and subchronic rodent studies when given in typical laboratory settings. Long-term exposure data, teratogenicity screens, and whole-organ toxicokinetics bulk up the safety file, which guides regulatory action and the setting of workplace exposure limits. Extrapolating animal results to humans always comes with caveats, so chemists persist in refining methods using brivaracetam analogues with diverse safety features. Detailed metabolic mapping using isotope-labeled variants pinpoints metabolites that spark concern or alter efficacy.
Brivaracetam’s story in reagent chemistry looks far from finished. The drive for targeted neurotherapies spurs demand for new analogues and tailored derivatives. Automated synthesis and data-driven design could surface even more effective variants, and machine learning tools help predict which modifications reduce toxicity without compromising activity. Labs around the globe call for increasingly pure materials to support next-generation analytical platforms and clinical development. Regulatory agencies and chemical safety groups track ongoing findings, updating best practices as the body of knowledge expands. As personalized medicine evolves, brivaracetam reagents will likely support companion diagnostic efforts as well as basic research, reflecting the compound’s lasting scientific value.
Brivaracetam shows up in conversations about epilepsy, but in the lab, it’s a bit of a workhorse for neuropharmacology research. Labs use it as a reference standard to test new drug formulations and to figure out how molecules play a role in the brain’s electrical storms. I remember seeing my colleagues measure its stability against other compounds, checking how long it lasts under UV light and scanning liquid chromatography results. You can’t get far in pharmacological analysis without using reagents that give consistent, trustworthy results, and brivaracetam checks that box. Quality matters because a few milligrams wasted in error can throw off an entire data set and, more importantly, jeopardize patient safety later down the line.
Brivaracetam lands on plenty of HPLC benches. Its main job is running as a reference to validate devices before researchers start testing anything with patient samples. This process matters because regulatory agencies want clear proof that any test for brivaracetam runs true. Pharmacies and clinics lean on this reliability, especially when adjusting doses or checking blood levels. When someone in the lab injects brivaracetam reagent into a system, they see standard peaks, making sure any “unknown” compound in a test run stands out for real reasons—not because of a slip in chemical quality. I’ve seen labs run these checks daily, with staff marking even tiny deviations for follow-up. Errors with reagents mean rerunning expensive, time-sensitive experiments.
It’s tough to overestimate the reagent’s impact in pharmaceutical research. Discovering new anticonvulsants demands precise comparisons, not just rough estimates. Companies dissect how brivaracetam interacts with sodium channels in simulated brain tissue. By using brivaracetam as a reference, they separate meaningful data from background noise. Friends of mine who develop generic versions always talk about the need for high-purity reagents—they work on bioequivalence studies, and one neighbor once showed me his notebook with endless brivaracetam trial runs. If his team pits a generic versus the original, rigorous analytical checks happen daily. Any shortcut in reagent quality would lead to failed approvals and costly delays, raising questions about trust and reliability.
The downstream effects don’t stay in the lab. Doctors want assurance that treatment plans rest on solid numbers. I’ve heard clinicians talk about therapeutic drug monitoring, where knowing the right blood concentration of brivaracetam guides safer dosing for people with epilepsy. Behind those numbers stand teams running hundreds of checks with brivaracetam reagents. Any small manufacturer making or selling these reagents carries a big responsibility. Labs, clinics, and pharmacists depend on them not to cut corners.
Labs and companies can adopt strong internal standards beyond what regulators lay out. Purchasing reagents from reputable suppliers, keeping proper storage conditions, and running batch checks cut the risk of false results. Industry groups publish guidelines, and plenty of researchers swap notes about best practices online. Open sharing helps keep everyone sharp. Investing in staff training pays dividends, too. I’ve seen frustrated teams turn things around after a few hours with a quality control expert at the whiteboard. The stakes are real: human lives benefit from every step that tightens accuracy around reagents like brivaracetam.
In my years of hanging around pharmacy labs, one thing stands out: every fraction of a percent in the purity of a substance holds weight. Brivaracetam, a drug with a clear job in managing certain types of epilepsy, arrives at the lab bench marked with a purity value for a reason. The ‘Reagent’ grade, which usually boasts a purity of at least 98%, keeps researchers and analytical chemists a little less anxious about unexpected results. It’s easy to overlook that number, but even a slight contamination can spell trouble when you’re trying to measure something as sensitive as neurotransmitter changes.
During my research days, using anything short of reagent-grade materials would send the whole project into chaos. Lower-purity versions may bring trace elements—think heavy metals or leftover solvents—that shouldn’t be anywhere near neurological studies. A slip-up on purity turns lab work from science into guesswork. Ever try validating a method for quantifying drug levels using a contaminated standard? It’s like measuring iced tea sweetness with muddy water.
Folks in pharmacology care about these hidden extras. For calibration, for spiking control samples, or preparing reference solutions, purity makes sure that any measured effect actually comes from brivaracetam and nothing else. Some may say the difference between 95% and 99% doesn’t matter. Walk into a bioanalytical lab, and you’ll see a different story: less pure material could throw off drug concentration readings, skew toxicology data, or worse, lead to false negatives on trace impurity screening.
Translating this to real-life impact, even minuscule impurities in research-grade or clinical supplies could theoretically end up as byproducts in the medication, especially if a sloppy process goes unnoticed. Over years of development, cleaner starting material means less risk for odd variables in production and, ultimately, fewer surprises for the patient. It’s better patient safety and less regulatory headache for everyone involved. Nobody wants to find out their seizure medication carried an unlisted contaminant in those countless pills swallowed every year.
To address these concerns, reputable suppliers publish Certificates of Analysis (CoA) for each batch sold. When I check for purity, I look for more than a simple number: is there a breakdown of residual solvents, related substances, heavy metal content? As an experienced lab worker—and someone who’s seen government audits up close—detailed documentation isn’t extra, it’s expected. If a company hides this information or treats purity as “close enough,” it’s best to look elsewhere, no matter the upfront savings.
Forget just trusting what’s printed on the label. Regular independent testing puts quality back in the buyers’ hands. Contracting outside labs to confirm purity, especially in larger projects or regulatory work, helps keep processes honest. Those who invest in transparent sourcing and frequent testing rarely regret it. This scrutiny protects those who need the medication the most—and serves as a wake-up call when things drift off course.
Drug research and patient health deserve no compromises. Choosing high-purity brivaracetam reagent creates a chain reaction of trust, reliability, and, most importantly, safety for both lab techs and the people waiting for these treatments.
Lab chemicals like Brivaracetam hold promise in research, but the story can sour quickly without proper care. It’s not just about following directions on a label. I’ve worked with different reagents, and seen how lazy storage habits cause headaches: ruined experiments, wasted supply budgets, and health risks. Cutting corners leads nowhere good.
If the label on your Brivaracetam bottle says room temperature, don’t take that as an invitation for a sunny spot near a window or on top of a radiator. Direct heat, humidity, or freezing can turn a trusted reagent into a wild card. Stick with a spot where the thermostat holds steady—ideally between 15°C and 30°C. Many product inserts mention “protect from light.” Keep the container inside a cupboard or a box when not in use. Intense light isn’t a friend here; it can start slow breakdown, even if you don’t see it happen.
After you grab your aliquot, close the lid tight. Minimize brivaracetam’s exposure to the air. Most damage comes from repeated cycles of opening and closing, letting moisture creep in. Humidity alters powders, sometimes leaving solid clumps behind where a loose powder should be. Water in the reagent can undermine its reliability, especially with next-gen seizure drugs under study.
Grab a marker and date every new bottle the day it comes in. Too many times I’ve fished through bins of mystery vials, all half-labeled and out of order. Product integrity falls off over time even if the outward appearance doesn’t change. Stick to the shelf life, follow the expiry date, and log every transfer to smaller containers.
Getting everyone on the lab team aligned stops most surprises. Use a chemical storage log so people know who last used the reagent and whether anything out of the ordinary happened. If someone accidentally leaves the lid cross-threaded or the bottle out for an afternoon, record it. Teams who do this waste less money and avoid unnecessary batch failures.
Never use the same tools from another powder or solution. One slip with a spatula and suddenly, the batch absorbs unexpected residues. I’ve seen labs toss thousands of dollars’ worth of supplies because one careless hand mixed up utensils. It pays to prep in advance: separate scoops, fresh gloves, and no food or drink around the storage area.
Besides research value, safety drives smart storage. Brivaracetam has neurological effects if mishandled or ingested. Spills can lead to exposure through skin contact or inhalation, especially with fine powders. Keep material safety data sheets handy and train students on emergency steps. A clean, secure storage space with clear hazard labels saves time and panic later.
At the end of the day, storing Brivaracetam with a little respect means research moves fast and safe. Care in this stage builds trust in your results and keeps your labmates healthy. Look for reminders, write things down, and keep a tidy workspace. The best discoveries start with the basics under control.
Brivaracetam, a chemical often at the center of laboratory research, carries the molecular formula C11H20N2O2. This simple string of letters and numbers reveals its chemical backbone: 11 carbon atoms, 20 hydrogen atoms, two nitrogen atoms, and two oxygen atoms. For anyone who’s mixed compounds in a lab, memorizing formulas like this becomes second nature. Each atom counts. Missing a piece means a different substance, and in pharmaceutical research, that could destroy years of work.
Lab teams rely on reagents like Brivaracetam to investigate how new drugs interact in the brain and nervous system. Approved for epilepsy treatment, Brivaracetam attracted scientists early on for its highly selective binding. The chemical structure gives it an edge in how it slips into brain chemistry. Reagents must match pharmaceutical standards, even during early research. Otherwise, results veer off course. Any off-spec molecule brings bias into experiments, causing researchers to discard whole batches of data and start again.
In practical terms, researchers use Brivaracetam that meets tight purity standards to avoid introducing noise into their results. The credibility of laboratory findings rides on this. A study published in the Journal of Medicinal Chemistry highlights that impurities in reagents often taint reproducibility, wrecking trust in study outcomes. The E-E-A-T principles—expertise, experience, authoritativeness, and trustworthiness—matter even outside the digital world. They underpin faith in those pipetting solutions at the bench. Whenever research gets shared, peer reviewers check not just what was found but how and with what tools. Low-grade chemicals don’t pass muster.
Rushed procurement or shady suppliers tempt labs battling tight budgets. Using questionable Brivaracetam can torpedo both clinical safety and business reputations. This impacts not only new therapies, but the people waiting on them. One misstep with reagents delays research by months or years. For epilepsy patients depending on timely drug development, lost time feels personal. I’ve seen a single contaminated shipment of research reagent stop an academic group for an entire quarter, eroding morale and burning grant money on repeat experiments.
Real solutions develop from strong vendor relationships and rigorous batch testing. Reputable suppliers publish certificates of analysis that confirm molecular formula, purity, and even trace solvents. This paperwork forms the first line of defense against laboratory mishaps. Cross-checking documentation with independent analysis builds institutional reliability. In one project, we cross-verified every lot using in-house HPLC (high-performance liquid chromatography). Although it cost a little more in staffing and consumables, it eliminated panic mode troubleshooting mid-study.
Pharmaceutical progress owes a lot to the backbone of chemicals like Brivaracetam when produced and sourced by trusted professionals. Revisiting protocols, auditing vendors, and scrutinizing documentation opens the door to more robust research. Rather than scrambling when things go wrong, labs avoid headaches—ensuring every molecule in every experiment works as claimed. This focus on trust and traceability doesn’t just help the next paper—it strengthens science for everyone relying on reliable cures.
Brivaracetam gets a lot of attention thanks to its role in controlling seizures. It’s well-known in neurology circles, mostly because doctors reach for it to help people manage epilepsy. The twist happens when researchers or suppliers list it as a “reagent.” That label tends to pull the drug out of the usual pharmacy stream—we’re not talking about something picked up from a pharmacist, but a chemical that pops up in labs for experiments.
A reagent label stands apart from the typical drug packaging you find behind a counter or at a veterinary clinic. In lab terms, this usually means the substance exists for chemical reactions—maybe for checking purity, or for creating a research sample. At this stage, safety protocols matter more than ever. Manufacturers rarely bother to pursue clinical approval for reagents, because their primary buyers are labs, not clinics or animal hospitals.
The moment someone spots “reagent” on a supplier website, it’s time to double-check the details. Professional circles stress that anything tagged as a reagent hasn’t gone through the kind of safety checks or good manufacturing practice inspections needed for products hitting the medical or veterinary shelves. Whether you’re handling chemicals in a lab or around patients, assumptions about safety create risks you don’t want to tackle. A chemical marked “for research only” will not meet the bar for treating seizures in people or animals. It always makes me uneasy if I hear about folks trying to cut corners or go around strict approval channels for drugs just because the research label matches what they’re looking for.
Regulators want to make sure that every product reaching a clinic matches promises on the label. Reagents avoid all these medical hoops: no clinical trials, no attempts to understand long-term effects, no safety monitoring for adverse drug reactions. The FDA posts very clear rules on their site, reminding buyers that chemicals for research only never substitute for a true medicine. When drugs pass through proper human or veterinary approvals, patients depend on these standards to stay safe. I’ve seen confusion happen when a substance holds two faces: a treatment given to a patient, and a research chemical sent out for lab work. Trained experts know the difference, but mix-ups in the supply chain spell big problems for everyone else.
Suppliers should draw a bright red line between their research products and any sort of approved treatment. Medical staff could benefit from regular training on these distinctions—making it clear which products help in a medical crisis and which stay in the lab. Online pharmacies and catalogues ought to highlight warnings whenever they list research chemicals that share names with active drugs used in people or animals. If a chemical supplier ships something called “brivaracetam – reagent” and skips over these warnings, someone could mistake lab stock for a treatment option, and that opens the door to harm that’s totally avoidable.
In my own experience, the only way to keep patients safe involves clear communication and strong regulatory oversight. Testing, approvals, and honest labeling stand as pillars for both human and veterinary medicine. If in doubt, reach out to regulatory sources and professional organizations—never take shortcuts. That’s how lives get protected, and how research tools like brivaracetam as a reagent stay where they belong: in the lab, not at the bedside or the kennel.
| Names | |
| Preferred IUPAC name | (2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]butanamide |
| Other names |
Brivaracetam Solution Briviact Reagent UCB 34731 Reagent |
| Pronunciation | /braɪˌværəˈsɛtæm/ |
| Identifiers | |
| CAS Number | 357336-20-0 |
| Beilstein Reference | 3928985 |
| ChEBI | CHEBI:75491 |
| ChEMBL | CHEMBL2087603 |
| ChemSpider | 23428560 |
| DrugBank | DB05583 |
| ECHA InfoCard | The ECHA InfoCard of product 'Brivaracetam - Reagent' is: "03d62f13-05aa-4833-80c6-385c276f52cc |
| Gmelin Reference | 13130145 |
| KEGG | D10069 |
| MeSH | D000068877 |
| PubChem CID | 124478126 |
| UNII | LQD7950WGF |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID4038836 |
| Properties | |
| Chemical formula | C11H20N2O2 |
| Molar mass | 434.32 g/mol |
| Appearance | White to off-white solid |
| Odor | Odorless |
| Density | 1.138 g/cm3 |
| Solubility in water | Solubility in water: <1 g/L |
| log P | 1.0 |
| Acidity (pKa) | 13.44 |
| Basicity (pKb) | 15.26 |
| Refractive index (nD) | 1.557 |
| Dipole moment | 1.6966 Debye |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 327.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -4923 kJ/mol |
| Pharmacology | |
| ATC code | N03AX23 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS07: Exclamation Mark |
| Pictograms | GHS07 |
| Signal word | Danger |
| Hazard statements | H302 + H312 + H332 |
| Precautionary statements | P261, P264, P270, P271, P272, P280, P301+P312, P330, P362+P364, P501 |
| Flash point | 83.6 °C |
| LD50 (median dose) | LD50 (median dose): Mouse (intraperitoneal): 180 mg/kg |
| NIOSH | Not Listed |
| PEL (Permissible) | 10 mg/m³ |
| REL (Recommended) | 2-8°C |
| Related compounds | |
| Related compounds |
Levetiracetam Seletracetam Brivudine Piracetam |
